NCT02377752 2021-02-17
A Study of Olaratumab in Japanese Participants With Advanced Cancer
Eli Lilly and Company
Phase 1 Completed
Clinical Trials
3 trialsNCT01199822 2017-04-14
Study of the Safety and Pharmacokinetics of Olaratumab (IMC-3G3) in Japanese Participants With Solid Tumors
Eli Lilly and Company
Phase 1 Completed
NCT00768391 2011-06-28
Study of IMC-3G3 in Patients With Tumors That Are Not Responding to Standard Therapies or No Therapy is Available
Eli Lilly and Company
Phase 1 Completed